Market Summary
USD550.13-19.51
Market Closed-3.42%
LLY Stock Price
LLY RSI Chart
LLY Valuation
LLY Price/Sales (Trailing)
LLY Profitability
LLY Fundamentals
LLY Revenue
LLY Earnings
Price Action
52 Week Range
299.13601.84
(Low)(High)
Last 7 days
-7.0%
Last 30 days
-0.6%
Last 90 days
19.9%
Trailing 12 Months
86.1%
LLY Financial Health
LLY Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for LLY
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-18 | Hedley Mary Lynne | acquired | 9,711 | 571 | 17.00 | - |
2023-09-18 | Alvarez Ralph | acquired | 11,425 | 571 | 20.00 | - |
2023-09-18 | Fyrwald J Erik | acquired | 9,711 | 571 | 17.00 | - |
2023-09-18 | LUCIANO JUAN R | acquired | 14,282 | 571 | 25.00 | - |
2023-09-18 | JOHNSON KIMBERLY H | acquired | 9,711 | 571 | 17.00 | - |
2023-09-18 | Sulzberger Gabrielle | acquired | 5,141 | 571 | 9.00 | - |
2023-09-12 | Weems Alonzo | gifted | - | - | -760 | evp, erm & ceco |
2023-09-12 | Weems Alonzo | sold | -678,445 | 590 | -1,148 | evp, erm & ceco |
2023-09-07 | LILLY ENDOWMENT INC | sold | -119,995,000 | 571 | -210,000 | - |
2023-08-31 | Dozier Eric | gifted | - | - | -546 | evp, hr & diversity |
Which funds bought or sold LLY recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -2.44 | 1,915,870 | 7,681,890 | 3.22% |
2023-09-14 | Proquility Private Wealth Partners, LLC | sold off | -100 | -913,353 | - | -% |
2023-09-13 | CGC Financial Services, LLC | new | - | 1,876 | 1,876 | -% |
2023-09-12 | Prosperity Financial Group, Inc. | added | 5.87 | 205,928 | 667,828 | 0.59% |
2023-09-12 | Farther Finance Advisors, LLC | added | 385 | 1,413,960 | 1,665,350 | 0.36% |
2023-09-12 | Prosperity Wealth Management, Inc. | new | - | 214,355 | 214,355 | 0.14% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | added | 308 | 318,006 | 387,377 | 0.11% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 798,204 | 798,204 | 0.04% |
2023-09-07 | JAG CAPITAL MANAGEMENT, LLC | added | 26.72 | 6,148,770 | 14,565,700 | 1.68% |
2023-09-07 | Strategic Financial Concepts, LLC | added | 4.22 | 86,199 | 289,867 | 0.11% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Eli Lilly and
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 7.73% | 73,429,863 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.9% | 65,467,793 | SC 13G/A | |
| Jan 25, 2023 | lilly endowment inc | 10.83% | 102,948,810 | SC 13G/A | |
| Feb 11, 2022 | pnc financial services group, inc. | 5.42% | 51,888,455 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 7.24% | 69,261,754 | SC 13G/A | |
| Feb 08, 2022 | blackrock inc. | 6.7% | 63,877,023 | SC 13G/A | |
| Jan 27, 2022 | lilly endowment inc | 11.23% | 107,463,810 | SC 13G/A | |
| Feb 12, 2021 | pnc financial services group, inc. | 5.44% | 52,012,151 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.18% | 68,661,494 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 6.1% | 58,811,768 | SC 13G/A |
Recent SEC filings of Eli Lilly and
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 13, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 07, 2023 | 144 | Notice of Insider Sale Intent |
Peers (Alternatives to Eli Lilly and)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 495.0B | 29.5B | -0.64% | 86.07% | 76.18 | 16.77 | 1.53% | 14.16% |
JNJ | 420.1B | 97.8B | -2.63% | 0.36% | 32.18 | 4.3 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -0.47% | 27.98% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 185.5B | 77.9B | -10.83% | -24.56% | 8.64 | 2.38 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -4.49% | -14.30% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.73% | 596.48% | -74.02 | 4.1K | -86.94% | 71.24% |
PRGO | 4.4B | 4.6B | -13.48% | -15.45% | -65.31 | 0.95 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -19.97% | -1.08 | 2.5 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -13.44% | -19.42% | 34.58 | 2.36 | 0.62% | -24.59% |
INVA | 843.4M | 244.3M | -2.42% | 7.48% | 4.28 | 3.45 | -39.50% | -4.99% |
CRON | 807.9M | 109.5M | 20.45% | -29.10% | -5.63 | 7.38 | -2.66% | -32.13% |
ACRS | 482.6M | 31.2M | -9.55% | -49.48% | -4.58 | 15.49 | 407.54% | -26.47% |
CGC | 422.3M | 453.3M | 90.89% | -73.90% | -0.34 | 0.93 | -16.04% | 55.90% |
OCUL | 258.3M | 54.6M | -16.41% | -43.89% | -2.85 | 4.73 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Eli Lilly and News
Returns for LLY
Cumulative Returns on LLY
29.1%
10-Year Cumulative Returns
33.8%
7-Year Cumulative Returns
41.0%
5-Year Cumulative Returns
55.6%
3-Year Cumulative Returns
Risks for LLY
What is the probability of a big loss on LLY?
14.2%
Probability that Eli Lilly and stock will be more than 20% underwater in next one year
0%
Probability that Eli Lilly and stock will be more than 30% underwater in next one year.
0%
Probability that Eli Lilly and stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does LLY drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Eli Lilly and was unfortunately bought at previous high price.
Drawdowns
Financials for Eli Lilly and
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 6.6% | 29,516 | 27,691 | 28,541 | 29,240 | 29,071 | 29,323 | 28,318 | 27,759 | 26,726 | 25,486 | 24,540 | 23,214 | 22,950 | 23,087 | 22,320 | 21,843 | 21,673 | 21,622 | 21,493 | 21,262 | 20,916 |
| S&GA Expenses | 4.5% | 6,932 | 6,632 | 6,440 | 6,389 | 6,353 | 6,414 | 6,432 | 6,394 | 6,385 | 6,148 | 6,121 | 6,265 | 6,109 | 6,246 | 6,214 | 6,209 | 6,254 | 6,154 | 5,975 | 5,387 | 5,509 |
| R&D Expenses | 7.6% | 8,140 | 7,566 | 7,191 | 7,093 | 6,996 | 6,869 | 6,931 | 6,761 | 6,521 | 6,256 | 5,976 | 5,829 | 5,745 | 5,757 | 5,595 | 5,405 | 5,305 | 5,174 | 5,051 | 4,885 | 4,944 |
| EBITDA | -100.0% | - | 7,732 | 8,329 | 8,143 | 7,842 | 8,366 | 7,703 | 8,254 | 8,422 | 8,579 | 8,706 | 7,873 | 7,771 | 7,516 | 6,650 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.28* | 0.29* | 0.28* | 0.27* | 0.29* | 0.27* | 0.30* | 0.32* | 0.34* | 0.35* | 0.34* | 0.34* | 0.33* | 0.30* | - | - | - | - | - | - |
| Earnings Before Taxes | 15.9% | 7,281 | 6,283 | 6,806 | 6,550 | 6,230 | 6,733 | 6,156 | 6,785 | 6,977 | 7,026 | 7,230 | 6,424 | 6,393 | 6,215 | 5,266 | 4,534 | 4,470 | 3,046 | 3,680 | 3,140 | 2,391 |
| EBT Margin | -100.0% | - | 0.23* | 0.24* | 0.22* | 0.21* | 0.23* | 0.22* | 0.24* | 0.26* | 0.28* | 0.29* | 0.28* | 0.28* | 0.27* | 0.24* | - | - | - | - | - | - |
| Net Income | 14.3% | 6,498 | 5,687 | 6,245 | 6,033 | 5,692 | 6,129 | 5,582 | 5,972 | 6,071 | 6,093 | 6,194 | 5,573 | 5,618 | 5,533 | 8,318 | 7,948 | 7,843 | 6,256 | 3,232 | 450 | -143 |
| Net Income Margin | -100.0% | - | 0.21* | 0.22* | 0.21* | 0.20* | 0.21* | 0.20* | 0.22* | 0.23* | 0.24* | 0.25* | 0.24* | 0.24* | 0.24* | 0.37* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 6,292 | 7,084 | 7,661 | 7,108 | 8,063 | 7,261 | 6,919 | 7,095 | 7,815 | 6,500 | 6,648 | 6,352 | 4,908 | 4,837 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 3.1% | 54,814 | 53,163 | 49,490 | 47,462 | 47,064 | 46,919 | 48,806 | 48,187 | 47,809 | 46,838 | 46,633 | 43,946 | 41,967 | 41,103 | 39,286 | 37,893 | 38,666 | 38,007 | 43,908 | 44,625 | 42,359 |
| Current Assets | 2.5% | 21,332 | 20,811 | 18,035 | 17,640 | 17,115 | 16,965 | 18,452 | 17,808 | 17,296 | 16,605 | 17,462 | 16,240 | 14,582 | 13,994 | 13,710 | 12,662 | 13,455 | 12,598 | 20,550 | 20,686 | 18,333 |
| Cash Equivalents | -24.0% | 2,695 | 3,546 | 2,067 | 2,617 | 2,623 | 2,459 | 3,819 | 3,788 | 3,220 | 3,002 | 3,657 | 3,595 | 2,365 | 1,699 | 2,338 | - | 2,290 | 2,036 | 7,321 | 8,960 | 6,817 |
| Inventory | 5.6% | 4,799 | 4,545 | 4,310 | 3,831 | 3,899 | 3,893 | 3,886 | 3,907 | 3,825 | 3,661 | 3,980 | 3,555 | 3,314 | 3,102 | 3,191 | 3,101 | 3,181 | 3,055 | 3,098 | 4,118 | 4,156 |
| Net PPE | 6.9% | 11,277 | 10,546 | 10,144 | 9,311 | 9,128 | 9,103 | 8,985 | 8,920 | 8,856 | 8,630 | 8,682 | 8,281 | 7,981 | 7,898 | 7,873 | 7,802 | 7,848 | 7,780 | 7,996 | 8,814 | 8,771 |
| Goodwill | 0.1% | 4,079 | 4,073 | 4,073 | 3,892 | 3,892 | 3,892 | 3,892 | 3,884 | 3,884 | 3,877 | 3,767 | 3,726 | 3,723 | 3,779 | 3,679 | 3,773 | 3,820 | 3,856 | 1,367 | 4,358 | - |
| Current Liabilities | 18.1% | 18,915 | 16,010 | 17,138 | 15,653 | 15,621 | 13,386 | 15,053 | 13,682 | 15,093 | 11,714 | 12,482 | 11,977 | 11,989 | 12,610 | 11,775 | 10,829 | 11,855 | 11,236 | 11,888 | 10,827 | 13,055 |
| LT Debt, Non Current | -3.8% | 18,158 | 18,881 | 14,738 | 14,144 | 14,692 | 15,153 | 15,346 | 15,522 | 14,737 | 16,200 | 16,587 | 16,335 | 15,064 | 13,982 | 13,818 | 13,662 | 13,718 | 13,610 | 9,196 | 11,675 | 9,171 |
| Shareholder's Equity | -1.1% | 11,064 | 11,190 | 10,650 | 10,070 | 8,545 | 9,331 | 8,979 | 7,757 | 6,444 | 6,899 | 5,642 | 4,827 | 4,093 | 3,079 | 2,607 | 3,383 | 2,781 | 2,480 | 9,829 | 13,077 | 11,555 |
| Retained Earnings | -2.5% | 10,369 | 10,639 | 10,043 | 10,007 | 8,556 | 9,369 | 8,959 | 9,639 | 8,530 | 9,181 | 7,830 | 7,154 | 6,617 | 5,879 | 4,920 | 4,982 | 4,318 | 4,879 | 11,396 | 14,409 | 14,247 |
| Additional Paid-In Capital | 2.3% | 6,949 | 6,793 | 6,921 | 6,829 | 6,746 | 6,656 | 6,833 | 6,758 | 6,669 | 6,579 | 6,779 | 6,699 | 6,629 | 6,556 | 6,685 | 6,609 | 6,535 | 5,757 | 6,584 | 6,523 | 5,826 |
| Accumulated Depreciation | 1.4% | 10,632 | 10,486 | 10,233 | 10,074 | 10,120 | 10,138 | 9,977 | 9,963 | 9,842 | 9,643 | 9,571 | 9,601 | 9,297 | 9,142 | 9,162 | 9,055 | 8,956 | 8,792 | 8,667 | 9,672 | 9,566 |
| Shares Outstanding | -0.1% | 900 | 901 | - | 901 | 900 | 904 | - | 907 | 907 | 909 | - | 907 | 907 | 908 | - | 914 | 921 | 980 | - | 1,020 | 1,030 |
| Minority Interest | -18.2% | 86.00 | 105 | 126 | 96.00 | 115 | 131 | 176 | 197 | 219 | 201 | 184 | 169 | 179 | 118 | 92.00 | 80.00 | 77.00 | 85.00 | 1,080 | 1,074 | 66.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -8.8% | 5,741 | 6,292 | 7,084 | 7,661 | 7,494 | 8,086 | 7,261 | 6,919 | 7,095 | 7,815 | 6,500 | 6,648 | 6,352 | 4,908 | 4,837 | 4,322 | 4,933 | 5,399 | 5,525 | 5,819 | 5,579 |
| Share Based Compensation | 17.3% | 471 | 401 | 371 | 354 | 359 | 358 | 343 | 355 | 337 | 322 | 308 | 302 | 306 | 308 | 312 | 304 | 297 | 287 | 280 | 279 | 280 |
| Cashflow From Investing | 12.6% | -2,545 | -2,912 | -3,261 | -2,780 | -2,859 | -2,516 | -2,762 | -3,057 | -2,754 | -2,481 | -2,258 | -1,626 | -1,736 | -1,465 | -8,082 | -8,700 | -8,674 | -5,602 | 1,906 | 4,218 | 2,858 |
| Cashflow From Financing | -43.0% | -3,025 | -2,116 | -5,406 | -5,791 | -4,991 | -5,951 | -4,131 | -3,896 | -3,712 | -4,302 | -3,137 | -2,959 | -4,373 | -3,585 | -2,324 | -2,850 | -725 | -670 | -5,904 | -4,807 | -4,739 |
| Dividend Payments | 3.7% | 3,802 | 3,668 | 3,536 | 3,425 | 3,313 | 3,198 | 3,087 | 2,984 | 2,885 | 2,791 | 2,687 | 2,604 | 2,520 | 2,444 | 2,410 | 2,395 | 2,380 | 2,362 | 2,312 | 2,288 | 2,263 |
| Buy Backs | 0% | 750 | 750 | 1,500 | 2,250 | 2,250 | 2,750 | 1,250 | 500 | 500 | - | 500 | 800 | 1,400 | 1,400 | 4,400 | 5,200 | 5,600 | 6,551 | 4,151 | 3,151 | 2,151 |
LLY Income Statement
2023-06-30Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue (Note 2) | $ 8,312.1 | $ 6,488.0 | $ 15,272.1 | $ 14,298.0 |
| Costs, expenses, and other: | ||||
| Cost of sales | 1,807.4 | 1,430.5 | 3,434.1 | 3,502.6 |
| Research and development | 2,356.5 | 1,781.9 | 4,341.6 | 3,392.0 |
| Marketing, selling, and administrative | 1,925.4 | 1,625.1 | 3,674.6 | 3,183.0 |
| Acquired in-process research and development (Note 3) | 97.1 | 440.4 | 202.1 | 606.0 |
| Other–net, (income) expense (Note 10) | 36.8 | 119.2 | 1.1 | 469.9 |
| Costs, expenses, and other | 6,223.2 | 5,397.1 | 11,653.5 | 11,153.5 |
| Income before income taxes | 2,088.9 | 1,090.9 | 3,618.6 | 3,144.5 |
| Income taxes (Note 6) | 325.7 | 138.4 | 510.5 | 289.1 |
| Net income | $ 1,763.2 | $ 952.5 | $ 3,108.1 | $ 2,855.4 |
| Earnings per share: | ||||
| Basic (in dollars per share) | $ 1.96 | $ 1.06 | $ 3.45 | $ 3.17 |
| Diluted (in dollars per share) | $ 1.95 | $ 1.05 | $ 3.44 | $ 3.16 |
| Shares used in calculation of earnings per share: | ||||
| Basic (in shares) | 899.7 | 900.3 | 900.3 | 902.0 |
| Diluted (in shares) | 902.7 | 902.9 | 903.0 | 904.4 |
LLY Balance Sheet
2023-06-30Consolidated Condensed Balance Sheets - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets | ||
| Cash and cash equivalents (Note 5) | $ 2,694.5 | $ 2,067.0 |
| Short-term investments (Note 5) | 134.6 | 144.8 |
| Accounts receivable, net of allowances of $13.8 (2023) and $16.0 (2022) | 7,516.1 | 6,896.0 |
| Other receivables | 1,655.3 | 1,662.9 |
| Inventories | 4,798.7 | 4,309.7 |
| Prepaid expenses and other current assets | 4,532.4 | 2,954.1 |
| Total current assets | 21,331.6 | 18,034.5 |
| Investments (Note 5) | 2,745.1 | 2,901.8 |
| Goodwill | 4,078.9 | 4,073.0 |
| Other intangibles, net | 6,903.5 | 7,206.6 |
| Deferred tax assets | 3,805.9 | 2,792.9 |
| Property and equipment, net of accumulated depreciation of $10,631.6 (2023) and $10,233.4 (2022) | 11,277.4 | 10,144.0 |
| Other noncurrent assets | 4,671.6 | 4,337.0 |
| Total assets | 54,814.0 | 49,489.8 |
| Current Liabilities | ||
| Short-term borrowings and current maturities of long-term debt | 661.6 | 1,501.1 |
| Accounts payable | 2,474.2 | 1,930.6 |
| Employee compensation | 867.7 | 1,059.8 |
| Sales rebates and discounts | 10,389.9 | 8,784.1 |
| Dividends payable | 1,016.2 | 1,017.2 |
| Income taxes payable | 1,233.8 | 475.1 |
| Other current liabilities | 2,271.6 | 2,370.3 |
| Total current liabilities | 18,915.0 | 17,138.2 |
| Other Liabilities | ||
| Long-term debt | 18,158.4 | 14,737.5 |
| Accrued retirement benefits (Note 7) | 1,308.8 | 1,305.1 |
| Long-term income taxes payable | 3,330.7 | 3,709.6 |
| Other noncurrent liabilities | 1,951.8 | 1,824.0 |
| Total other liabilities | 24,749.7 | 21,576.2 |
| Commitments and Contingencies (Note 8) | ||
| Eli Lilly and Company Shareholders' Equity | ||
| Common stock | 593.6 | 594.1 |
| Additional paid-in capital | 6,948.6 | 6,921.4 |
| Retained earnings | 10,368.5 | 10,042.6 |
| Employee benefit trust | (3,013.2) | (3,013.2) |
| Accumulated other comprehensive loss (Note 9) | (3,788.7) | (3,844.6) |
| Cost of common stock in treasury | (45.0) | (50.5) |
| Total Eli Lilly and Company shareholders' equity | 11,063.8 | 10,649.8 |
| Noncontrolling interests | 85.5 | 125.6 |
| Total equity | 11,149.3 | 10,775.4 |
| Total liabilities and equity | $ 54,814.0 | $ 49,489.8 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.